• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

缺铁定义为铁储存耗尽伴细胞铁需求未得到满足,可识别出急性心力衰竭发作后死亡风险最高的患者。

Iron deficiency defined as depleted iron stores accompanied by unmet cellular iron requirements identifies patients at the highest risk of death after an episode of acute heart failure.

机构信息

Laboratory for Applied Research on Cardiovascular System, Department of Heart Diseases, Wrocław Medical University, Wrocław, Poland Cardiology Department, Centre for Heart Diseases, Military Hospital, ul. Weigla 5, Wrocław 50-981, Poland

Laboratory of Molecular and Cellular Immunology, Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Wrocław, Poland.

出版信息

Eur Heart J. 2014 Sep 21;35(36):2468-76. doi: 10.1093/eurheartj/ehu235. Epub 2014 Jun 13.

DOI:10.1093/eurheartj/ehu235
PMID:24927731
Abstract

AIM

Acute heart failure (AHF) critically deranges haemodynamic and metabolic homoeostasis. Iron is a key micronutrient for homoeostasis maintenance. We hypothesized that iron deficiency (ID) defined as depleted iron stores accompanied by unmet cellular iron requirements would in this setting predict the poor outcome.

METHODS AND RESULTS

Among 165 AHF patients (age 65 ± 12 years, 81% men, 31% de novo HF), for ID diagnosis we prospectively applied: low serum hepcidin reflecting depleted iron stores (<14.5 ng/mL, the 5th percentile in healthy peers), and high-serum soluble transferrin receptor (sTfR) reflecting unmet cellular iron requirements (≥1.59 mg/L, the 95th percentile in healthy peers). Concomitance of low hepcidin and high sTfR (the most profound ID) was found in 37%, isolated either high sTfR or low hepcidin was found in 29 and 9% of patients, and 25% of subjects demonstrated preserved iron status. Patients with low hepcidin and high sTfR had peripheral oedema, high NT-proBNP, high uric acid, low haemoglobin (P < 0.05), and 5% in-hospital mortality (0% in remaining patients). During the 12-month follow-up, 33 (20%) patients died. Those with low hepcidin and high sTfR had the highest 12-month mortality [(41% (95% CI: 29-53%)] when compared with those with isolated high sTfR [15% (5-25%)], isolated low hepcidin [7% (0-19%)] and preserved iron status (0%) (P < 0.001). Analogous mortality patterns were seen separately in anaemics and non-anaemics.

CONCLUSION

Iron deficiency defined as depleted body iron stores and unmet cellular iron requirements is common in AHF, and identifies those with the poor outcome. Its correction may be an attractive therapeutic approach.

摘要

目的

急性心力衰竭(AHF)严重扰乱了血液动力学和代谢的动态平衡。铁是维持动态平衡的关键微量营养素。我们假设,在这种情况下,定义为铁储备不足伴有未满足的细胞铁需求的缺铁(ID)将预示着不良预后。

方法和结果

在 165 名 AHF 患者(年龄 65 ± 12 岁,81%为男性,31%为新发 HF)中,我们前瞻性地应用以下方法诊断 ID:低血清铁调素反映铁储备不足(<14.5ng/mL,健康人群中第 5 百分位数),高血清可溶性转铁蛋白受体(sTfR)反映未满足的细胞铁需求(≥1.59mg/L,健康人群中第 95 百分位数)。低铁调素和高 sTfR 同时存在(最严重的 ID)见于 37%的患者,单独存在高 sTfR 或低铁调素见于 29%和 9%的患者,25%的患者铁状态正常。低铁调素和高 sTfR 的患者外周水肿、高 NT-proBNP、高尿酸、低血红蛋白(P<0.05),住院期间死亡率为 5%(其余患者为 0%)。在 12 个月的随访期间,有 33 名(20%)患者死亡。与单独存在高 sTfR[15%(5-25%)]、单独存在低铁调素[7%(0-19%)]和铁状态正常(0%)相比,低铁调素和高 sTfR 的患者 12 个月死亡率最高[41%(95%CI:29-53%)](P<0.001)。在贫血和非贫血患者中,均观察到类似的死亡模式。

结论

定义为体内铁储备不足和未满足的细胞铁需求的缺铁在 AHF 中很常见,并确定了预后不良的患者。纠正缺铁可能是一种有吸引力的治疗方法。

相似文献

1
Iron deficiency defined as depleted iron stores accompanied by unmet cellular iron requirements identifies patients at the highest risk of death after an episode of acute heart failure.缺铁定义为铁储存耗尽伴细胞铁需求未得到满足,可识别出急性心力衰竭发作后死亡风险最高的患者。
Eur Heart J. 2014 Sep 21;35(36):2468-76. doi: 10.1093/eurheartj/ehu235. Epub 2014 Jun 13.
2
High soluble transferrin receptor in patients with heart failure: a measure of iron deficiency and a strong predictor of mortality.心力衰竭患者可溶性转铁蛋白受体水平升高:缺铁的一项指标及死亡率的有力预测因素
Eur J Heart Fail. 2021 Jun;23(6):919-932. doi: 10.1002/ejhf.2036. Epub 2020 Dec 4.
3
Conventional and novel peripheral blood iron markers compared against bone marrow in Malawian children.常规和新型外周血铁标志物与马拉维儿童骨髓的比较。
J Clin Pathol. 2014 Aug;67(8):717-23. doi: 10.1136/jclinpath-2014-202291. Epub 2014 Jun 10.
4
Elevated lactate in acute heart failure patients with intracellular iron deficiency as identifier of poor outcome.急性心力衰竭伴细胞内铁缺乏患者的血乳酸升高可作为预后不良的标志物。
Kardiol Pol. 2019;77(3):347-354. doi: 10.5603/KP.a2019.0014. Epub 2019 Feb 11.
5
Hepcidin-25 vs. conventional clinical biomarkers in the diagnosis of functional iron deficiency.铁调素-25与传统临床生物标志物在功能性缺铁诊断中的比较
Eur J Haematol. 2015 Dec;95(6):507-13. doi: 10.1111/ejh.12523. Epub 2015 Feb 23.
6
Clinical characteristics and predictors of in-hospital mortality in 270 consecutive patients hospitalised due to acute heart failure in a single cardiology centre during one year.270 例急性心力衰竭患者在单中心心内科住院期间的临床特征及院内死亡的预测因素分析。
Kardiol Pol. 2011;69(10):997-1005.
7
Imbalance of Iron Availability and Demand in Patients With Acute and Chronic Heart Failure.铁的供给与需求失衡与急慢性心力衰竭患者。
J Am Heart Assoc. 2024 May 7;13(9):e032540. doi: 10.1161/JAHA.123.032540. Epub 2024 Apr 19.
8
Iron status in patients with chronic heart failure.慢性心力衰竭患者的铁状态。
Eur Heart J. 2013 Mar;34(11):827-34. doi: 10.1093/eurheartj/ehs377. Epub 2012 Nov 23.
9
Soluble TNFα receptor type I and hepcidin as determinants of development of anemia in the long-term follow-up of heart failure patients.可溶性肿瘤坏死因子受体 I 和铁调素作为心力衰竭患者长期随访中贫血发展的决定因素。
Clin Biochem. 2012 Nov;45(16-17):1455-8. doi: 10.1016/j.clinbiochem.2012.05.011. Epub 2012 May 17.
10
Iron metabolism, hepcidin, and anemia in orthotopic heart transplantation recipients treated with mammalian target of rapamycin.雷帕霉素靶蛋白治疗的原位心脏移植受者的铁代谢、铁调素与贫血
Transplant Proc. 2013 Jan-Feb;45(1):387-90. doi: 10.1016/j.transproceed.2012.02.040.

引用本文的文献

1
Iron Metabolism in Cardiovascular Disease.心血管疾病中的铁代谢
Adv Exp Med Biol. 2025;1480:217-236. doi: 10.1007/978-3-031-92033-2_15.
2
Hepcidin and Tissue-Specific Iron Regulatory Networks.铁调素与组织特异性铁调节网络
Adv Exp Med Biol. 2025;1480:89-102. doi: 10.1007/978-3-031-92033-2_7.
3
The protective effect of iron isomaltoside on myocardial ischemia-reperfusion injury via the suppression of KLF4/NF-κB signaling.低分子右旋糖酐铁通过抑制KLF4/NF-κB信号传导对心肌缺血再灌注损伤的保护作用。
PLoS One. 2025 Jun 5;20(6):e0323247. doi: 10.1371/journal.pone.0323247. eCollection 2025.
4
Iron Deficiency Is Associated With Impaired Myocardial Reperfusion in ST-Segment-Elevation Myocardial Infarction: Influence of the Definition Used.缺铁与ST段抬高型心肌梗死患者心肌再灌注受损相关:所用定义的影响。
J Am Heart Assoc. 2025 Jun 3;14(11):e040845. doi: 10.1161/JAHA.124.040845. Epub 2025 May 22.
5
Diagnosis and treatment of iron deficiency in chronic heart failure : Position statement of the heart failure working group of the Austrian Society of Cardiology.慢性心力衰竭中铁缺乏的诊断与治疗:奥地利心脏病学会心力衰竭工作组立场声明
Wien Klin Wochenschr. 2025 Mar;137(Suppl 3):143-156. doi: 10.1007/s00508-025-02521-x. Epub 2025 May 6.
6
Iron Deficiency in Heart Failure - the Relevance for the Patient: Proceedings of a Satellite Symposium Held at the ESC Congress 2014, 1 September 2014, Barcelona, Spain.心力衰竭中的缺铁——对患者的影响:2014年9月1日于西班牙巴塞罗那举行的欧洲心脏病学会(ESC)2014年大会卫星研讨会会议记录
Card Fail Rev. 2015 Apr;1(Suppl 1). doi: 10.15420/cfr.2015.1.1.S1.
7
Iron deficiency in patients with cardiogenic shock: protocol for a scoping review.心源性休克患者的缺铁:一项范围综述方案
BMJ Open. 2025 Apr 19;15(4):e092891. doi: 10.1136/bmjopen-2024-092891.
8
Anemia Management in the Cardiorenal Patient: A Nephrological Perspective.心肾疾病患者的贫血管理:肾脏病学视角
J Am Heart Assoc. 2025 Mar 4;14(5):e037363. doi: 10.1161/JAHA.124.037363. Epub 2025 Mar 3.
9
Versatile Nanomaterials That Interfere with Ferroptosis in the Tumor Microenvironment.可干预肿瘤微环境中铁死亡的多功能纳米材料
Int J Nanomedicine. 2025 Feb 25;20:2461-2473. doi: 10.2147/IJN.S508767. eCollection 2025.
10
The interplay of ferroptosis and oxidative stress in the pathogenesis of aortic dissection.铁死亡与氧化应激在主动脉夹层发病机制中的相互作用。
Front Pharmacol. 2025 Feb 5;16:1519273. doi: 10.3389/fphar.2025.1519273. eCollection 2025.